Vivo Bio Tech opened higher at ₹14.69, compared with its previous close of ₹14.43. During today's session, the stock has traded between ₹13.93 and ₹15.48, with an average traded price of ₹14.26. It is currently showing a downward intraday trend.
An investment of ₹10,000 made 1 year ago in Vivo Bio Tech is now worth
₹ 7,266.00
resulting in a loss of
₹ 2,734.00 (27.34%)
Note: Past profits do not guarantee future returns.
No analyst rating data available.
Today's Change
-0.13 (-0.90%)
Day High
₹15.48
Day Low
₹13.93
Day Open
₹14.69
Prev Close
₹14.43
Volume
24,547
Value Traded
₹0.04 Cr
1W Return
-5.55%
1M Return
-16.52%
3M Return
-27.34%
6M Return
-27.34%
1Y Return
-27.34%
Market Cap (₹ Cr.)
32
PE Ratio
-11.20
PB Ratio
0.35
Dividend Yield
-
ROE
-1.83%
ROCE
7.19%
Book Value (₹)
41.25
Face Value (₹)
10.00
EPS (TTM)
0.08
Industry PE
-
Beta
-
Debt to Equity
-
1 Week
-5.55%
6 Week
-
1 Month
-16.52%
3 Month
-27.34%
9 Month
-27.34%
Vivo Bio Tech dispatches FY26 annual report web-link ahead of Sept 30 AGM
Vivo Bio Tech dispatched web-links for FY26 annual report to unregistered email shareholders. 39th AGM scheduled for September 30, 2026, to re-appoint directors and adopt accounts. Company posted a net loss of ₹193.61 crore in FY26 vs profit of ₹757.08 crore in FY25. Total income rose to ₹5,300.93 crore in FY26 from ₹5,147.74 crore in prior year.
1mo agoMaxcell Communication transfers 12 lakh Vivo Bio Tech shares off-market
Maxcell Communication India Pvt Ltd transferred 12,00,000 Vivo Bio Tech shares off-market on August 21, 2026. The transfer reduced the promoter group entity's stake from 5.41% to nil. The disclosure was made under SEBI Regulation 29(2) to the BSE. Vivo Bio Tech's total equity capital remains unchanged at 2,21,90,628 shares. Diluted capital includes 6,27,409 warrants and 63,22,000 ESOPs.
1mo agoDwight Technologies acquires 5.41% stake in Vivo Bio Tech
Dwight Technologies acquired 12,00,000 shares (5.41%) in Vivo Bio Tech via off-market deal. Total holding rises to 30,72,561 shares, representing 13.85% of voting capital. Transaction reported under SEBI SAST Regulations Regulation 29(2). Acquirer is not part of the promoter group of Vivo Bio Tech.
1mo agoVivo Bio Tech promoter group entity P.K.L Solution transfers 6 lakh shares
P.K.L Solution Private Limited transferred 6,00,000 equity shares off-market. The transaction reduced the promoter group entity's stake from 2.70% to nil. Total equity share capital remains at 2,21,90,628 shares. Diluted capital includes 6,27,409 warrants and 63,22,000 ESOPs. Disclosure filed under SEBI SAST Regulations 29(2).
1mo agoVivo Bio Tech sets Sept 30 AGM, reappoints three directors
Vivo Bio Tech schedules 39th AGM for September 30, 2026, via VC/OVAM. Board reappoints Mr Kalyan Ram Mangipudi who retires by rotation. Mr Sri Kalyan Kompella gets five-year term starting November 2026. Dr Sankaranarayanan Alangudi appointed for five years starting January 2027. Board approves annual reports for FY26 financial year ended March 31, 2026.
1mo agoVivo Bio Tech returns to profit in Q1FY26 with revenue growth
Vivo Bio Tech Limited returned to profitability in Q1FY26 with a consolidated net profit of ₹18.76 lakh, compared to a net loss of ₹516.27 lakh in the previous quarter. Revenue from operations increased to ₹1,427.97 lakh. The Board approved the unaudited financial results on July 13, 2026.
3mo ago| Stock | LTP | Change % | Market Cap (Cr.) | PE | 1Y Return |
|---|---|---|---|---|---|
| ₹870.15 | -1.52% | ₹49,035.39 | 86.41 | +8.66% | |
| ₹267.35 | +0.24% | ₹2,971.63 | 17.39 | -12.77% |
An investment of ₹10,000 made 1 year ago in Vivo Bio Tech is now worth
₹ 7,266.00
resulting in a loss of
₹ 2,734.00 (27.34%)
Note: Past profits do not guarantee future returns.
